The PEPR projects are grouped under 4 main axes:

Axis 1 – Anticipate the scale-up of cell therapies and the emergence of tissue therapies

Axis 2 – Accelerate the deployment of gene therapies

Axis 3 – Engineering to benefit biotherapies and bioprocesses

Axis 4 – Support an emerging industrial sector centered around the use of extracellular vesicles

loader
loader

ACCREDIA

ACCelerating Research for Early Development of Innovative Antibodies

21 December 2024

Read more

BACTER-EV-BOOSTER

Multidisciplinary approach to stimulate the bioproduction and engineering of Gram+ bacteria’s Extracellular Vesicles (EVs) for therapeutic applications to treat inflammation

21 December 2024

Read more

Bioengineered Skin-France

Bioengineering of next-generation skin substitutes for cutaneous regeneration

21 December 2024

Read more

BIOSCALE

Improving the whole chain of large scale AAV bioproduction through disruptive technologies

21 December 2024

Read more

CARN

Development of biotherapies based on the local delivery of therapeutic RNAs by hybrid functionalized extracellular vesicles (EVs) for musculoskeletal regeneration

21 December 2024

Read more

EDITO

Development of breakthrough technologies in gene editing

21 December 2024

Read more

iCHONDRO

Generation of iChondrocytes to regenerate articular cartilage

21 December 2024

Read more

iPSC France

Genomic editing of stable universal pluripotent stem cells for allogeneic cell biotherapies

21 December 2024

Read more

QualAAV

Innovative approaches for quality control to support the industrial deployment of future gene therapy products.

21 December 2024

Read more

RNAvac

New generation of mRNA-based vaccines

21 December 2024

Read more

STROMAEV

From engineering of iPS-derived mesenchymal stromal cell-derived extracellular vesicles to clinical translation

21 December 2024

Read more

THERA-B

B-cell genetic engineering for new therapeutic and vaccine modalities

21 December 2024

Read more